Clorox (CLX)
NYSEConsumer StaplesHousehold & Personal ProductsSnapshot 2026-07-07
$97.42+0.17%
Close 2026-07-07 · 1-day change
Reading CLX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CLX free→NYSEConsumer StaplesHousehold & Personal ProductsSnapshot 2026-07-07
Reading CLX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CLX free→QuarterlyIQ Insights · CLX
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 12 valuation methods, at three horizons. Current price $97.42. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $97 CLX trades at 14× p/e, below its 19× p/e peer median, but our blended $87 fair value sits below the price. It's a high-confidence read. Analysts target $83–$139. Not investment advice.
$83.00 – $139.00 (median $97.00) · 9 analysts · as of 2026-05-01
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 99% over what the business is worth with no growth; closing that gap needs roughly 9.0 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $2.66/sh owner earnings.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q3, 2026-Q1, 2026-Q2, 2026-Q3
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $97.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $13.79 | — | — | Hist. CAGR | high |
| ddm gordon | 12M | $14.49 | — | — | TTM | high |
| graham number | 12M | $10.71 | — | — | TTM | high |
| Mgmt guidance | 12M | $106.85 | 19.3 | 5.55 | Mgmt | high |
| Peer EV/EBITDA | 12M | $122.28 | 16.9 | 8.67 | TTM | high |
| Peer P/FCF | 12M | $63.47 | 20.3 | 3.12 | TTM | high |
| Peer P/E | 12M | $129.95 | 19.3 | 6.75 | TTM | high |
| Peer P/S | 12M | $94.40 | 1.7 | 55.51 | TTM | high |
| residual income | 12M | $25.83 | — | — | TTM | high |
| Own P/E history | 12M | $117.31 | 17.4 | 6.75 | TTM | high |
| triangulated | 12M | $140.36 | 19.3 | 7.29 | Triangulated | high |
| Mgmt guidance | 3Y | $83.94 | 19.3 | 4.36 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $28.71 | 20.3 | 1.41 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $102.09 | 19.3 | 5.30 | Analyst | medium |
| Peer P/S | 3Y | $117.99 | 1.7 | 69.38 | guidance | medium |
| Own P/E history | 3Y | $92.16 | 17.4 | 5.30 | Analyst | medium |
| Mgmt guidance | 5Y | $71.47 | 19.3 | 3.71 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $16.92 | 20.3 | 0.83 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $86.93 | 19.3 | 4.52 | Analyst | high |
| Peer P/S | 5Y | $146.69 | 1.7 | 86.25 | guidance | high |
| Own P/E history | 5Y | $78.47 | 17.4 | 4.52 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.